Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-191011 (BMS-A) is an activator of large-conductance calcium-activated potassium (BKCa) channels ,effective in stroke models
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 51.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 163.00 | |
50 mg | In stock | $ 308.00 | |
100 mg | In stock | $ 463.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 58.00 |
Description | BMS-191011 (BMS-A) is an activator of large-conductance calcium-activated potassium (BKCa) channels ,effective in stroke models |
In vivo | In vivo, BMS 191011 (10-100 μg/kg, i.v.) increases the diameter of retinal arterioles without affecting blood pressure or heart rate in rats, an effect that is reversed by the BKCa channel blocker iberiotoxin[1] |
Synonyms | BMS-A |
Molecular Weight | 370.71 |
Formula | C16H10ClF3N2O3 |
CAS No. | 202821-81-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (337.19 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-191011 202821-81-6 Membrane transporter/Ion channel Potassium Channel rodent models of stroke Panc-1 neuroprotective activity inhibit IGR39 Inhibitor BMS 191011 BMS-A BMS191011 KcsA inhibitor